chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A report was received from a health care professional on 12/16/03 concerning a group of 5 vaccinees aged less than 4 years of age and of unknown gender who were inadvertently administered Fluvirin on an unknown date. On an unknown date, a group of 5 vaccinees aged less than 4 years of age and of unknown gender were inadvertently administered Fluvirin. No adverse events have occurred as a result of this at the time of this report. There was insufficient information to determine the reporter's causality assessment. Update 3/26/04: A follow up report was received from a health care professional indicating that a 2 year old female vaccinee inadvertently received 0.25 Fluvirin on 11/5/03. The vaccinee did not experience any adverse symptoms as a result. Follow up pending.
Twelve hours after receiving the dose she had a heart attack; underwent a Spontaneous Coronary Artery Dissection; This spontaneous case was reported by a consumer and describes the occurrence of MYOCARDIAL INFARCTION (Twelve hours after receiving the dose she had a heart attack) and CORONARY ARTERY DISSECTION (underwent a Spontaneous Coronary Artery Dissection) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, the patient experienced MYOCARDIAL INFARCTION (Twelve hours after receiving the dose she had a heart attack) (seriousness criterion medically significant) and CORONARY ARTERY DISSECTION (underwent a Spontaneous Coronary Artery Dissection) (seriousness criterion medically significant). At the time of the report, MYOCARDIAL INFARCTION (Twelve hours after receiving the dose she had a heart attack) and CORONARY ARTERY DISSECTION (underwent a Spontaneous Coronary Artery Dissection) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2021, Antibody test: showed very strong antibodies showed very strong antibodies. In September 2021, Antibody test: showed no antibodies showed no antibodies.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medication was reported.    No treatment medications were reported.  Company comment: This case concerns a 49-year-old female patient, with no reported medical history, who experienced the serious  (medically significant according to list and per medical judgment), unexpected events of myocardial infarction and coronary artery dissection. The events occurred 12 hours after the patient received the first dose of mRNA 1273 COVID-19 vaccine. Patient had antibody tests which showed that after 1 month after the vaccine, her antibodies were very strong but after 5 months, she had no antibodies. The patient did not receive the second dose due to the adverse events. At the time of report, outcome of events were unknown and no treatment information were given. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.; Sender's Comments: This case concerns a 49-year-old female patient, with no reported medical history, who experienced the serious  (medically significant according to IME list and per medical judgment), unexpected events of myocardial infarction and coronary artery dissection. The events occurred 12 hours after the patient received the first dose of mRNA 1273 COVID-19 vaccine. Patient had antibody tests which showed that after 1 month after the vaccine, her antibodies were very strong but after 5 months, she had no antibodies. The patient did not receive the second dose due to the adverse events. At the time of report, outcome of events were unknown and no treatment information were given. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.
Pregnancy confirmed 1/28/2021, 5 weeks 5 days. Pregnancy lost 1/31/2021.  Symptoms after Moderna vaccine were low fever and pain at injection site.
Chills, headache, earache, body aches, nausea, chest pain, tiredness. Began at 12:30 am on Sept 24, lasted all day. No appetite.  By the night of the 24th the symptoms were chest pain, mild nausea, mild body aches, sore eyes (felt dry), and tiredness.  On Sept 25 the only remaining symptoms were chest pain and tiredness. By the morning of the 26th all symptoms were resolved, other than mild chest pain, which was probably attributable to my ongoing vasospastic angina.
74-year-old female patient with past medical history of COPD, chronic kidney disease, hypertension, hyperlipidemia comes to the hospital with complaint of subjective fever and shaking chills for a week.  The patient never took temperature at home.  Today the patient's condition got worsen she vomited x2 therefore came to ER.  The patient denies shortness of breath, cough, chest pain, back pain, urinary symptoms, diarrhea and constipation.
Initial report was received 15 July 2011 from a health care professional. An 18-year-old male patient had received an intramuscular left deltoid injection of MENACTRA, lot number U4008AA and an intramuscular left deltoid injection of PENUMOVAX 23 (manufacturer Merck, lot number 0930Z) on 11 July 2011 and within 24 hours post vaccination, he developed a fever 101-102 degrees Fahrenheit, a headache, nausea and complained of a red, painful arm with limited range of motion. He had not received any other vaccines within the four weeks prior, he had no concurrent illness, and he had not experienced any adverse events following prior vaccinations. The patient had a history of asthma. Concomitant medications consisted of Albuterol prn and SYNTHROID  2.5 mcg. Outcome was not recovered. Documents held by sender: None.
Employee was called 5 hours after medication administration, referring improved but still having Shortness of breath. Referred will go to the ER if symptoms continue
Erythema right shoulder 4x5cm. Warmth started 24 hours after injection
Covid symptoms started 12/31/2021 with sore throat, fever, and sinus congestion. By 01/02/2022 I was fully congested in my head and still had a fever, bad sore throat, and a productive cough where I was coughing up phlegm and had drainage. I went to urgent care and tested positive on 01/02/2022. Symptoms lasted at least 7 days and by the 2nd week I only had a leftover cough.
This spontaneous report was received from a nurse, referring to a 2 month old patient of an unknown gender. The patient's historical conditions, concurrent conditions, concomitant therapies, historical drugs or allergies were unknown. On 28-NOV-2018, the patient was vaccinated with ROTATEQ, orally (strength, dose number, frequency, lot number and expiration date were not provided) for prevention of rotavirus. On the same date, immediately after vaccination the patient "spit it all up" (infantile spitting up and underdose). The outcome of infantile spitting up was reported as recovered/resolved. The patient did not receive any treatment for the event. No product quality complaint was reported. The causal relationship between infantile spitting up and vaccination with ROTATEQ was unknown.
Shortness of breath, fever, shivering, muscle ache, headache, soreness at injection site.
terrible headache; slight fever; chills; body aches; she only felt sore arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (she only felt sore arm), HEADACHE (terrible headache), PYREXIA (slight fever), CHILLS (chills) and MYALGIA (body aches) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. U58H212) for COVID-19 prophylaxis.     there was no  parental vaccine exposure.  The patient's past medical history included Sickness (On 3Jan2020 she was so sick for a week, she assumed was flu, but she never felt so sick in her life) on 03-Jan-2020. Concurrent medical conditions included Seasonal allergy.    On 02-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Dec-2021, after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (she only felt sore arm). On 05-Jan-2022, the patient experienced HEADACHE (terrible headache), PYREXIA (slight fever), CHILLS (chills) and MYALGIA (body aches). At the time of the report, VACCINATION SITE PAIN (she only felt sore arm), HEADACHE (terrible headache), PYREXIA (slight fever), CHILLS (chills) and MYALGIA (body aches) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: Negative and Negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Patient received her 1st Moderna dose of the primary series on 02 Dec 2021, and she only felt sore arm during 1 day. On 4Jan 2022 her husband (not previously vaccinated) tested positive to COVID-19. On 5 Jan 2022 she experienced COVID symptoms like terrible headache, slight fever, chills and body aches during 3 days, but she tested negative to COVID-19 twice.
Patient came down with a rash that was diffusely across his whole body. It was quite itchy and red.
I had a fever 103 and my arm was very sore and hurt all the way down to my hand. I had a hard time focusing and thinking and felt very depressed and tired. The fatigue was horrible and about 5 days later I still had a fever. I came home one day and laid on the bed and it felt like I was falling down continuously. I then slept for about 15 hours. It slowly went away after that and the fever came down to normal. I just felt like I was struggling really bad.
This is a spontaneous report from a contactable physician via a Pfizer sales representative. A female patient of an unspecified age and race/ethnicity received PREVNAR 13, via an unspecified route of administration, on an unspecified date, at single dose, for immunisation. Relevant medical history and concomitant medications were not reported. The patient experienced redness and swelling of arm from wrist to shoulder on an unspecified date with outcome of unknown, which caused patient's hospitalization. No follow-up attempts possible. No further information expected. Sender's Comments: A causal association between administration of PREVNAR 13 and the onset of events cannot be fully excluded, considering the temporal association. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
has been putting up with eye troubles; This spontaneous case was reported by a consumer and describes the occurrence of EYE DISORDER (has been putting up with eye troubles) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011A21A and 044A21A) for COVID-19 vaccination.     Concurrent medical conditions included High cholesterol, Diabetes and Blood pressure high.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In February 2021, the patient experienced EYE DISORDER (has been putting up with eye troubles). At the time of the report, EYE DISORDER (has been putting up with eye troubles) outcome was unknown.            concomitant medication were reported include High cholesterol-Diabetes-High blood pressure medication.  Treatment information not provided.
The caller stated the patient developed a rash/palmar lesions; The caller stated the patient developed a rash, cold like symptoms, and a fever; The caller stated, "Maybethe brother transmitted it to him."; had palmar lesions and that the lesions resemble hand, foot, mouth disease.; This spontaneous report has been received from a physician concerning to a 2-year-old child male patient.The patient's medical history, concurrent conditions, previous drug reactions or allergies were not provided. Concomitant therapies included sterile diluent.  On an unknown date (also reported as "when he was one year old"),the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection (strength, dose, vaccination scheme frequency, route of administration, anatomical location, lot number and expiration date were not provided) for prophylaxis. It was mentioned that the patient did not experience any symptoms at that time.  Then, on an unknown date, it was reported that the patient developed rash, cold like symptoms (nasopharyngitis) and fever at an unspecified time after his brother received both measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) and varicella virus vaccine live (oka/merck) (VARIVAX) concomitantly. The caller stated, "Maybe the brother transmitted it to him" (secondary transmission); the patient also experienced palmar lesions and that lessions resemble had, foot and mouth disease (hand-foot-and-mouth disease).  The outcome of the events was reported as recovering.  The causality assessment between the suspect therapy regarding the events, were not provided.   This is one of two reports referring to siblings.; Sender's Comments:  US-009507513-2209USA005673:case from his brother
No adverse event in pt. Was informed to report to vaers due to expired vaccination being administered to pt. Vaccine expired on 3/31/23 and administered on 4/3/23
A spontaneous report has been received from a pharmacist concerning a 10 year old, female patient. No medical history or concomitant medications taken. On 13-Nov-2015, nasal FLUMIST (intranasal) was administered in a pharmacy by a pharmacist for influenza vaccination. Lot number unknown. Pharmacist removed stopper by mistake and 0.2 ml went into one nostril. Pharmacist described that he was in a rush and when going to administer in the second nostril, realized he had accidentally given it all in one nostril. No adverse reactions were reported. The report was considered to be non-serious by the reporter.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 19-JAN-2017, the patient was vaccinated with an improperly stored dose of VARIVAX lot number M033906, expiration date 20-JUL-2018 (dose, route and anatomical location were not reported) for prophylaxis (incorrect product storage). The vaccine was exposed to temperature of -5 Fahrenheit (F) (-20 Celsius (C)) and to the lowest recorded temperature of -14 F (-25C) during 4 hours and 5 minutes. The storage type was reported as "data logger". There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested. Sender's Comments: US-009507513-1701USA012890: US-009507513-1701USA013083: US-009507513-1701USA013084: US-009507513-1701USA013085: US-009507513-1701USA013086: US-009507513-1701USA013087: US-009507513-1701USA013088: US-009507513-1701USA013089: US-009507513-1701USA013090: US-009507513-1701USA013091: US-009507513-1701USA013092: US-009507513-1701USA013093: US-009507513-1701USA013094: US-009507513-1701USA013095: US-009507513-1701USA013096: US-009507513-1701USA013097: US-009507513-1701USA013098: US-009507513-1701USA013099: US-009507513-1701USA013100: US-009507513-1701USA013101: US-009507513-1701USA013102: US-009507513-1701USA013103: US-009507513-1701USA013104: US-009507513-1701USA013105: US-009507513-1701USA013106: US-009507513-1701USA013108: US-009507513-1701USA013109: US-009507513-1701USA013110: US-009507513-1701USA013082.
Information has been received from a lawyer regarding a case in litigation concerning a male patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. On or about 02-NOV-2012 the patient was vaccinated with ZOSTAVAX, 1 DF, (lot# and route unknown) as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 09-OCT-2015 the patient was treated for a blistering vesicular outbreak which was diagnosed as herpes zoster also known as shingles. The patient has been prescribed valacyclovir hydrochloride (VALTREX) and prednisone for management of his persistent and painful symptoms. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses and pain and suffering, and other damages. Additional information has been requested.
Information has been received from a 13 year old female patient who in December 2009, was vaccinated with a dose of GARDASIL. In December 2009, the patient experienced weakness, lethargy, pins and needles in her fingers and toes and muscle pain after receiving the vaccination. The patient visited the doctor and was prescribed NOROXIN but no improvement was seen. At the time of the report, the patient had not recovered. Additional information has been requested.
Case was hospitalized 7 months after completing Covid vaccination series. * COVID-19 Assessment & Plan No interval development of resp or GI sxs. Covid test positive on 10/25; unclear duration of symptoms but had a negative test about 6 weeks ago. Pt is vaccinated. No changes seen on xray. Symptoms of malaise for several weeks. Likely that generalized malaise is being caused by her covid and complicated by poor baseline health with end stage COPD and history of breast cancer. No remdesivir indicated.  - Continue dexamethasone 6mg daily, D#4/10. - PT/OT to continue thru Home Health after discharge.  - Safety measures.  - PCP fu has been arranged.    Chronic respiratory failure with hypoxia   Assessment & Plan Stable on her usual O2 rate of 2L/min. No evidence of acute resp failure from Covid.  - Continue O2 per home regimen.
Heart rate up to 180 bpm and fever throughout the night. No concurrent shortness of breath,dizziness, or chest pain.
one-day history of fevers rigors and not feeling well.  She noted nausea vomiting and headache started around 11:00 a.m. the day before admission and she was unable to keep down solids or liquids.  She developed abdominal discomfort as well as generalized body aches.  She continued to feel unwell the day of admission subsequently came into the emergency department.
Chronic headache; Fatigue; fever; Body aches; Chills; This spontaneous case was reported by a physician and describes the occurrence of HEADACHE (Chronic headache), FATIGUE (Fatigue), PYREXIA (fever), MYALGIA (Body aches) and CHILLS (Chills) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 063h21a) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2022, the patient experienced HEADACHE (Chronic headache), FATIGUE (Fatigue), PYREXIA (fever), MYALGIA (Body aches) and CHILLS (Chills). At the time of the report, HEADACHE (Chronic headache) and FATIGUE (Fatigue) outcome was unknown and PYREXIA (fever), MYALGIA (Body aches) and CHILLS (Chills) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant and treatment medication was reported by the reporter. It was reported that the patient have had chronic headache and fatigue since receiving the booster shot and for first 3 days had mild fever and body aches and chills.
The same day: chills, fatigue, shivering, joint and muscle pain.  For the next few weeks: intense pain in old injury sites that had healed years ago: rotator cuffs, knee, feet, also pain in sites without injury such as my big toes, my hands, the knee that had never been injured. As of today: my hands still hurt,  my feet still hurt, the joint that connects to my right big toe now looks swollen and really hurts.
Initial report received from a patient on 17 August 2007. A 46 year old, female (with a history of allergies to trees, grass, shellfish, mycins, sulfa, PCN) developed aches and joint pain, 2 days after she received her third dose of IMOVAX (lot number A0208-2, route of administration not reported) in the left deltoid on 15 August 2007. The symptoms are much worse. She did not have any illness at the time of the vaccinations and was not any medications. She was not recovered. The patient also complained of sweating, chills, the night after she received her first dose of IMOVAX and IMOGAN - case detailed in case 2007-02826. She also felt lethargic, mildly achy and slightly nauseated, the day after she received her second dose of IMOVAX - case details in case 2007-02827. Follow-up information was received from a health professional on 24 September 2007. The patient had received IMOVAX (lot number A0208) injections intramuscularly on the following dates: dose one (08 August 2007, left deltoid), dose two (11 August 2007, right deltoid), dose three (15 August 2007, left deltoid), dose four (20 August 2007, right deltoid), and dose five (05 September 2007, left deltoid). Events occurred following dose three. According to the reporter, the outcome was "unknown".
Pt presented to triage nurse with complaints of injection site: pain, redness, swelling, stiffness and abdominal nausea. For 7 days after PREVNAR's injection.
Face tingling, small red, painful itchy "dots". Around mouth, forehead. Went to walk in clinic, prescribed Mupirocin oint and top. cortisone cr. Peeling and flaky skin.
woke up today with a cold; This is a spontaneous report received from a contactable reporter (Consumer) for a Pfizer sponsored program (159558). The reporter is the patient.  A female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administration date 17Apr2021 (Batch/Lot number: unknown) as dose 2, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1), administration date: 27Mar2021, for COVID-19 immunisation. The following information was reported: NASOPHARYNGITIS (non-serious) with onset 18Apr2021, outcome "unknown", described as "woke up today with a cold". Additional Information: Patient wants to know if she can take Sudafed.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Fever of 102.3 for 16 hours, chills, headache, uncontrollable shaking, nausea
On 08/28/2021 I had fatigue, body aches and headache. For first few days I stayed in bed and felt sick for the whole week. I continue to have periods of fatigue and overall tiredness. I tested positive for COVID-19 on 01/12/22 at my work site. Prior to that test I did take a home test and it was negative.